{"id":"W2520064697","doi":"10.18632/oncotarget.12065","title":"Targeting MET and EGFR crosstalk signaling in triple-negative breast cancers","year":2016,"lang":"en","type":"article","venue":"Oncotarget","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":81,"is_retracted":false,"has_abstract":true,"ca_institutions":"Vertex Pharmaceuticals (Canada)","funders":"","keywords":"Erlotinib; Triple-negative breast cancer; Crizotinib; Medicine; Cancer research; EGFR inhibitors; Gefitinib; Lapatinib; Receptor tyrosine kinase; Epidermal growth factor receptor; Crosstalk; Targeted therapy; Tyrosine kinase; Breast cancer; Lung cancer; Oncology; Cancer; Internal medicine; Receptor; Trastuzumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002653507,0.0004250025,0.000517957,0.0004245678,0.000282854,0.0008565607,0.000317695,0.0003806199,0.002477086],"category_scores_gemma":[0.0002220771,0.0001953546,0.0002840445,0.0002116717,0.0001578713,0.000310761,0.0005558687,0.0008967633,0.000911273],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007019429,"about_ca_system_score_gemma":0.0005988163,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008738887,"about_ca_topic_score_gemma":0.003835051,"domain_scores_codex":[0.9998335,0.0000198887,0.00000688615,0.00001990663,0.00006884209,0.00005093157],"domain_scores_gemma":[0.9999444,0.000007328481,0.00001145448,0.000003791596,0.00001140258,0.00002155191],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.002155529,0.0005282013,0.006013589,0.00114424,0.0001736459,0.0008444433,0.0001493244,0.001486183,0.7213893,0.001857186,0.01678777,0.2474706],"study_design_scores_gemma":[0.001506585,0.007013486,0.06430502,0.0007610806,0.0009682945,0.009185087,0.001172933,0.02462434,0.6346911,0.004602795,0.2510427,0.0001265866],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.7864655,0.1549893,0.009599498,0.00748657,0.0008927375,0.0003605802,0.000978863,0.001123518,0.03810336],"genre_scores_gemma":[0.9490528,0.03408461,0.003660335,0.001248913,0.0001353929,0.0001850762,0.0007259072,0.00006923718,0.01083774],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002477086,"threshold_uncertainty_score":0.008286655,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01032561367063748,"score_gpt":0.3110296367389623,"score_spread":0.3007040230683248,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}